Intellego Technologies AB (publ) (“Intellego” or the “Company”) announces that the product QIKcap, owned by its partner company HAI Solutions (HAIS), has today received approval from the U.S. Food and Drug Administration (FDA). The approval means that QIKcap may now be marketed and used within the U.S. healthcare system.

QIKcap is based on HAI Solutions’ patented technology, in which Intellego’s photochromic indicator technology constitutes an integrated and essential part of the now approved product.

Intellego holds an ownership interest of approximately 10.5 percent in HAIS and, in addition, has exclusive rights to sell QIKcap in the Chinese market. Intellego is also entitled to license revenues from global sales of the product.

“The FDA approval of QIKcap is an important milestone for HAI Solutions and enables future sales opportunities for Intellego in the Chinese market, as well as potential license revenues linked to global sales of QIKcap,” says Jacob Laurin, acting CEO of Intellego Technologies.

QIKcap is a single-use cap for intravenous access points, primarily catheters. The product combines a photochromic dosimeter and an optical lens to verify UVC exposure, with the aim of reducing the risk of intravenous contamination and bloodstream infections.

Link to HAI Solutions news: News — HAI Solutions

Link to FDA approval.

Contact

Jacob Laurin, acting CEO and Board Member, Intellego Technologies AB
E-post: jacob.laurin@intellego-technologies.com

About Us

Intellego Technologies develops and manufactures color indicators that show the effect of irradiation with, among other things, invisible ultraviolet light, UV light. Color indicators are used globally in, for example, the disinfection industry, the sunscreen industry, and the manufacturing industry. Intellego's indicators have been developed from the company's patented photochromic ink, which can be adapted to different wavelengths of light and various application areas across a range of different industries. Intellego Technologies was founded in 2011, is headquartered in Stockholm, and is listed on the Nasdaq First North Growth Market.

The company's Certified Adviser on the Nasdaq First North Growth Market Stockholm is Mangold Fondkommission AB.

Intellego's website: https://intellego-technologies.com/en/

Subscribe to Intellego's press releases: https://intellego-technologies.com/sv/pressmeddelanden/

Contact the communications team: communications@intellego-technologies.com

This information is information that Intellego Technologies is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-12-30 16:19 CET.

Attachments

Intellego’s partner HAI Solutions has received FDA approval for QIKcap

Läs mer på MFN